RxDoctor Payments Data

Ronald Hubbard, MD

Internal Medicine · Monroe, LANPI 1427031640

Payments from drug & device makers

$822in general payments, 2019–2025

Across 44 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$146
  • Pfizer$113
  • GSK$98
  • AbbVie$95
  • Abbott$68
  • Novartis$53
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$79096%
  • Education$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen8$146
Pfizer6$113
GSK6$98
AbbVie5$95
Abbott4$68
Novartis3$53
Insmed, Inc.2$32
Astellas Pharma US Inc2$32
Abiomed1$31
Gilead1$30
Phathom Pharmaceuticals, Inc.1$29
Dexcom, Inc.1$26
Bayer1$21
Braemar Manufacturing, LLC1$21
Exact Sciences1$14
Corcept Therapeutics1$13

How this compares

$822 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$176,677
Medicare patients
280
Services billed
3,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$119,593
JardianceEmpagliflozin129$116,726
OzempicSemaglutide57$75,255
TradjentaLinagliptin65$54,564
JanuviaSitagliptin Phosphate53$42,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$33,213
XareltoRivaroxaban34$31,191
MounjaroTirzepatide27$26,844
EntrestoSacubitril/Valsartan20$21,086
TrulicityDulaglutide11$18,177
MyrbetriqMirabegron27$14,618
NexiumEsomeprazole Magnesium11$14,251
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$10,155
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/712$7,243
Spiriva RespimatTiotropium Bromide14$7,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$113$124,664178 claims
GSKTrelegy Ellipta, Anoro Ellipta$98$38,96162 claims
NovartisEntresto$53$21,08620 claims
Astellas Pharma US IncMyrbetriq$32$14,61827 claims
AbbVieSynthroid$95$1,84434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →